Study #2023-0125
A phase I trial of concurrent intensity Modulated Radiation Therapy (IMRT) and Dabrafenib/Trametinib in BRAF mutated anaplastic or poorly differentiated Thyroid Cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Dabrafenib, Trametinib
Description
This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma
Study phase:
Phase I
Physician name:
Naifa Busaidy
Department:
Endocrine Neoplasia and HD
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.